Blood Cancer Journal

期刊全称

期刊缩写

Blood Cancer J.

涉及主题

医学生物内科学免疫学遗传学病理化学生物化学癌症研究肿瘤科基因外科白血病细胞生物学心理学多发性骨髓瘤精神科血液学骨髓淋巴瘤

期刊介绍

Blood Cancer Journal seeks to publish articles of the highest quality related to hematologic malignancies and related disorders. The Journal will consider for publication original research, reviews, guidelines and letters that are considered to be of high impact in the field. Topics of particular interest include, but are not limited to, the following: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics.

期刊ISSN

print: 2044-5385

历年影响因子

2025年	2024年	2023年	2022年	2021年	2020年	2019年	2018年
11.6	12.9	12.8	9.812	11.037	8.023	7.895	8.125

历年发表/被引量

年份	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
发表量	137	229	224	194	173	203	126	103	128	142	135	110
被引量	50	960	3252	3942	4764	11219	5988	4062	6720	6733	6009	6215

h-Index

自引率

2.30%

涉及的研究领域

ONCOLOGY-

2026年新锐分区

大类	小类	TOP期刊	综述期刊
1区	1区肿瘤学	是	N/A
1区	1区血液学	是	N/A

中科院2025年分区

大类	小类	TOP期刊	综述期刊
1区	1区血液学	是	否
1区	1区肿瘤学	是	否

WOS期刊分区

JCR学科分类

JCR分区学科名称	收录数据库	JCR分区	分区排名
HEMATOLOGY	SCIE	Q1	6/103
ONCOLOGY	SCIE	Q1	24/333

JCI学科分类

JCI分区学科名称	收录数据库	JCI分区	分区排名
HEMATOLOGY	SCIE	Q1	7/103
ONCOLOGY	SCIE	Q1	29/333

期刊主页

http://www.nature.com/bcj

投稿网址

http://mts-bcj.nature.com/cgi-bin/main.plex

出版商

Springer Nature

出版国家（地区）

ENGLAND

出版语言

English

每年出版文章数

115

Gold OA文章占比

99.68%

原创研究文献占比
(排除综述)

84.38%

SCI收录类型

Science Citation Index Expanded (SCIE)

Scopus (CiteScore)

Directory of Open Access Journals (DOAJ)

PubMed链接

http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2044-5385%5BISSN%5D

平均审稿周期

>12周，或约稿

平均录用比例

容易

Blood Cancer Journal

JCR学科分类

JCI学科分类

期刊相关文献 (2098)

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

套细胞淋巴瘤巩固治疗的治疗演变及对生存的影响：来自亚太真实世界注册研究的启示

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence

Pola-R-CHP 作为弥漫性大B细胞淋巴瘤一线治疗方案：随机试验和真实世界证据的系统评价和荟萃分析

Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study

固定剂量inotuzumab ozogamicin (INO)联合长春新碱和泼尼松(VP)方案作为新诊断B细胞急性淋巴细胞白血病(B-ALL)诱导治疗：一项多中心、开放标签、单臂、前瞻性临床研究

Chronic myeloid leukemia: incorporation of recent advances into current treatment algorithms

慢性粒细胞白血病：将最新进展纳入现有治疗方案

Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine

维奈托克、阿扎胞苷和粒细胞集落刺激因子靶向治疗对高剂量阿糖胞苷耐药的 CBFB::MYH11 AML 中的分子残留病灶

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study

罗伐替尼（一种首创的JAK/ROCK抑制剂）治疗骨髓纤维化患者的临床前和I期研究

Genomic landscape, clinical correlates and prognostic implications of U2AF1 mutation subtypes in myelodysplastic neoplasms

骨髓增生异常综合征中U2AF1突变亚型的基因组图谱、临床相关性及预后意义

The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma

orelabrutinib联合obinutuzumab（O2）作为边缘区淋巴瘤一线全身治疗的疗效、安全性和理论依据

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

克隆结构及TET2突变双等位基因失活对骨髓增生异常综合征的影响

Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

奥维瑞巴替尼联合免疫疗法与奥维瑞巴替尼联合异基因造血干细胞移植治疗新诊断的费城染色体阳性急性淋巴细胞白血病成人患者的疗效比较